Osteoporosis Management After Denosumab Discontinuation

Introduction to Denosumab Discontinuation

The European Society for Medical Oncology (ESMO) strongly recommends bisphosphonate treatment if denosumab is discontinued for more than 6 months to suppress rebound osteolysis and prevent vertebral fractures in patients with a history of osteoporosis 1
Denosumab discontinuation is associated with multiple vertebral fractures in some patients, highlighting the need for careful management of the transition period 2

If denosumab has been discontinued for more than 6 months, the American College of Oncology recommends starting bisphosphonate treatment immediately (preferably zoledronate) to prevent vertebral fractures and suppress rebound osteolysis 1
For patients restarting denosumab, ensuring vitamin D deficiency is corrected and maintaining adequate calcium supplementation throughout treatment is crucial, as recommended by the ESMO clinical practice guidelines 1
High-risk patients, such as those with previous fragility fractures or T-scores ≤-2.5, should receive particularly prompt intervention to prevent further bone loss and fractures 2

Measuring bone turnover markers (particularly CTX) is essential to assess the degree of bone resorption after denosumab discontinuation, as recommended by the ESMO clinical practice guidelines 2
For patients who have completed a course of an anabolic agent like romosozumab, denosumab should be started immediately afterward to maintain bone gains, although this recommendation is based on a lower level of evidence 4

Delayed intervention after denosumab discontinuation significantly increases fracture risk, emphasizing the need for prompt action 1
Inadequate calcium and vitamin D supplementation can compromise treatment efficacy, highlighting the importance of proper nutrition and supplementation in osteoporosis management 1